Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT05337657 Recruiting - Clinical trials for Advanced Breast Cancer

A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Start date: June 2, 2021
Phase: Phase 1
Study type: Interventional

GB491-005 is a multicenter, open-label, phase Ib Clinical Trial study to evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GB491 in combination with Letrozole in Previously Untreated Patients with HR-positive, HER2-negative Advanced Breast Cancer

NCT ID: NCT05337280 Completed - Breast Cancer Clinical Trials

OA for Breast Cancer NAC Response

Start date: March 30, 2021
Phase: N/A
Study type: Interventional

This is an early research and development study. The objective of this study is to determine the feasibility of the Imagio OA/US Breast Imaging System to detect complete breast cancer pathologic response to neoadjuvant therapy as assessed by functional optoacoustic features, vascular features and relative degrees of oxygenation/deoxygenation

NCT ID: NCT05336721 Recruiting - Clinical trials for Triple-negative Breast Cancer

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Start date: November 5, 2021
Phase: Phase 2
Study type: Interventional

This study is to evaluate the preliminary efficacy and safety of chiauranib in combine with capecitabine in advanced triple-negative breast cancer failed to prior anthracyclines and taxanes therapy

NCT ID: NCT05335473 Recruiting - Clinical trials for HR Positive HER2 Negative Advanced Breast Cancer

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

Start date: May 13, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

To explore the safety and efficacy of Eribulin plus Tucidinostat amine in patients with HR+/ HER2-advanced metastatic breast cancer

NCT ID: NCT05334810 Not yet recruiting - Clinical trials for HER2-positive Breast Cancer

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

This is a study of DP303c in patients with HER2-positive advanced breast cancer.

NCT ID: NCT05334732 Recruiting - Breast Cancer Clinical Trials

Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)

SIS
Start date: March 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to test an evidence-based intervention designed to increase adherence to systemic therapy in Black women compared to enhanced usual care.

NCT ID: NCT05334459 Recruiting - Clinical trials for Metastatic Breast Cancer

Preoperative Radiotherapy and Systemic Therapy Following Surgery in 'de Novo' Metastatic Breast Cancer

Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

Locoregional (LRT) of the primary tumor in de-novo metastatic breast cancer (dnMBC) is no longer only a surgical challenge, but more the final decision of a multidisciplinary tumor board including medical oncologists, radiation oncologists and surgical oncologists. It is no longer only a question of locoregional control but rather a wider issue of improving overall survival (OS), due to the possible biological link between primary tumor and metastases. A multimodal approach, including LRT with curative intent should be considered for selected dnMBC patients, especially for the subset of bone-only metastatic ones.

NCT ID: NCT05334147 Not yet recruiting - Clinical trials for HER2-negative Breast Cancer

Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer

ALOT-BC1
Start date: April 15, 2022
Phase:
Study type: Observational

The study is being conducted to evaluate the efficacy and safety of anlotinib combined with chemotherapy treatment for patients with HER2 negative advanced breast cancer previously received anthracyclines and taxanes

NCT ID: NCT05334069 Recruiting - Melanoma Clinical Trials

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Start date: August 1, 2022
Phase:
Study type: Observational

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

NCT ID: NCT05333874 Active, not recruiting - Clinical trials for Breast Cancer, Early-Onset

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

Start date: April 6, 2022
Phase: Early Phase 1
Study type: Interventional

Primary Objective: 1) To examine the impact of Circulating tumor DNA (ctDNA) (expressed as mean tumor molecules per ml) on treatment decision making in patients with early stage breast cancer after neoadjuvant therapy and surgery Secondary Objectives: 1. Understand ctNDA kinetics in the neoadjuvant and adjuvant setting 2. To identify any associations between clinical staging and measurable ctDNA